Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced that it has been granted a new patent.
Deltex Medical has been granted patent coverage for its innovative Combined Blood Flow and Blood Pressure Monitor. The granted coverage is for UK, Germany, France, Spain and Sweden. Coverage in the USA has been ‘allowed’ at this stage and the Company expects the US patent to be formally granted in the second half of the year.
The device filing covers use of Doppler measurements of central blood flow, measured with either oesophageal or suprasternal ultrasound probes, in conjunction with blood pressure signals whether measured in arteries, veins or by way of non invasive pressure cuffs placed on the arm or fingers. The coverage also includes the combination of a venous oxygen saturation sensor with the flow and pressure measurements.
Ewan Phillips, Deltex Medical Group Plc Chief Executive, commented: “This patent is very important. It underpins and protects our combination of Doppler ultrasound flow signals with blood pressure inputs on a single monitoring platform including the current CardioQ-ODM+ platform.
“Doing this offers us unique possibilities to advance haemodynamic monitoring. We recently received a €50,000 EU grant to support the clinical development of innovative new ‘TruVue’ graphical user intrerfaces which are driven by combining flow and pressure signals.”
